Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Current Leases (2019 - 2025)

Ocular Therapeutix has reported Current Leases over the past 7 years, most recently at $2.8 million for Q4 2025.

  • Quarterly results put Current Leases at $2.8 million for Q4 2025, up 45.73% from a year ago — trailing twelve months through Dec 2025 was $2.8 million (up 45.73% YoY), and the annual figure for FY2025 was $2.8 million, up 45.73%.
  • Current Leases for Q4 2025 was $2.8 million at Ocular Therapeutix, up from $2.8 million in the prior quarter.
  • Over the last five years, Current Leases for OCUL hit a ceiling of $2.8 million in Q4 2025 and a floor of $1.4 million in Q1 2021.
  • Median Current Leases over the past 5 years was $1.7 million (2023), compared with a mean of $1.9 million.
  • Biggest five-year swings in Current Leases: dropped 15.18% in 2024 and later surged 60.86% in 2025.
  • Ocular Therapeutix's Current Leases stood at $1.6 million in 2021, then fell by 1.54% to $1.6 million in 2022, then dropped by 0.81% to $1.6 million in 2023, then grew by 21.88% to $1.9 million in 2024, then skyrocketed by 45.73% to $2.8 million in 2025.
  • The last three reported values for Current Leases were $2.8 million (Q4 2025), $2.8 million (Q3 2025), and $2.6 million (Q2 2025) per Business Quant data.